Hester Biosciences Ltd

Hester Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift markedly, moving from expensive to very expensive territory. Despite a modest day gain of 1.27%, the company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios raise questions about its price attractiveness relative to peers and historical benchmarks.

Hester Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Hester Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a modest day gain of 0.25%, the stock’s technical indicators present a complex picture, with weekly signals showing mild bullish tendencies contrasting with monthly bearish trends. This nuanced technical landscape warrants a detailed analysis for investors seeking clarity amid mixed signals.

Hester Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from mildly bearish to a more pronounced bearish stance. Despite some mildly bullish weekly indicators, the overall technical landscape suggests caution for investors as key momentum and trend indicators signal weakening price strength.

Hester Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating. This change reflects evolving market perceptions of the stock’s price attractiveness amid fluctuating financial metrics and sector comparisons.

Hester Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Despite a broadly positive market environment, Hester Biosciences Ltd has fallen to a fresh 52-week low of Rs 1,250.95 on 1 Apr 2026, marking a 10.27% decline over the past year and underperforming the Sensex by a wide margin.

Hester Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Despite a broadly recovering market, Hester Biosciences Ltd has plunged to a fresh 52-week low of Rs 1,251 on 30 Mar 2026, marking a 5.15% decline intraday and extending its losing streak to two consecutive sessions with a cumulative fall of 9.44%.

Hester Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from mildly bearish to a more pronounced bearish trend. Despite some mildly bullish weekly indicators, the overall technical landscape remains cautious, with key metrics such as MACD, RSI, and moving averages signalling a challenging near-term outlook for the stock.

Hester Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 January 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 20 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Hester Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a subtle shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish trend. Despite a modest day gain of 1.64%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators, reflecting cautious investor sentiment amid broader market challenges.

Hester Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. Despite some mildly bullish weekly indicators, the overall technical landscape remains cautious, reflecting the stock’s recent underperformance relative to the broader market benchmarks.

Hester Biosciences Ltd has exhibited a subtle shift in price momentum, transitioning from a bearish to a mildly bearish technical trend. Despite a 3.48% gain on 17 Mar 2026, the stock’s technical indicators present a complex picture, with some oscillators signalling cautious optimism while others remain subdued. This nuanced movement warrants a detailed analysis for investors seeking clarity on the stock’s near-term trajectory.

Hester Biosciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a modest recovery in the past year, the stock’s recent price action and technical parameters suggest caution for investors amid weakening momentum and persistent downward pressures.

Hester Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Hester Biosciences Ltd has experienced a nuanced shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish trend. Despite a recent downgrade in its Mojo Grade to 'Sell' from 'Strong Sell', the stock exhibits mixed signals across key technical indicators such as MACD, RSI, and moving averages, reflecting a complex market sentiment in the Pharmaceuticals & Biotechnology sector.